# A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism

> **NCT04701203** · PHASE3 · COMPLETED · sponsor: **Ascendis Pharma Bone Diseases A/S** · enrollment: 84 (actual)

## Conditions studied

- Hypoparathyroidism
- Endocrine System Diseases
- Parathyroid Diseases

## Interventions

- **COMBINATION_PRODUCT:** TransCon PTH
- **COMBINATION_PRODUCT:** Placebo

## Key facts

- **NCT ID:** NCT04701203
- **Lead sponsor:** Ascendis Pharma Bone Diseases A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-16
- **Primary completion:** 2022-01-12
- **Final completion:** 2025-01-21
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04701203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04701203, "A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04701203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*